News

orange__line
50% Recruitment Stage 1 in DxCARTES Study

MedSIR is delighted to announce that DxCARTES study achieves a new milestone: 50% recruitment completed in stage 1. We currently have 15 patients recruited and 39 screenings have been sent to Central lab...
READ MORE...
First Patient in BARBICAN Study

We are very pleased to announce that the first two Spanish patients have been successfully randomized in the Study by Dr. Viñas and her team from Hospital Josep Trueta (ICO) last June and have started treatment...
READ MORE...
First Patient in REVERT study

Welcome to the first patient in REVERT study. This is a multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally- recurrent or metastatic breast cancer patients...
READ MORE...
ASCO Annual Meeting 2019 Highlights

The 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) was characterized by a great number of presentations of novel and potentially practice-changing clinical trial data. The event was held...
READ MORE...
A great moment for MedSIR in OM3d

The IV Foro en Oncología Médica en 3 Días (OM3d) was celebrated on May 8 to 10, and MedSIR was there attending it in Madrid Teatro Goya. This is the most important congress with Spanish oncologists...
READ MORE...
First Patient In DxCARTES study

MedSIR has enrolled the first patient in DxCARTES: Neoadjuvant letrozole and palbociclib in patients with stage II-IIIB breast cancer, HR/HER2 phenotype and pre-treatment Recurrence Score® (RS)...
READ MORE...
DxCARTES study Poster Presentation at AACR 2019

Neoadjuvant endocrine therapy (NET) is a standard approach for elderly – unfit patients with an Endocrine Receptor positive Early Breast Cancer (EBC). However, for younger - fit patients this option is not generally...
READ MORE...
First Patient In PALMIRA study

MedSIR has enrolled the first patient in PALMIRA study, “PALbociclib rechallenge in horMone receptor-posItive/HER2-negative Advanced breast cancer”. This first patient has been enrolled at site Hospital Arnau de Vilanova...
READ MORE...
The BARBICAN Trial: TNBC’s first line of defense

"BARBICAN" is a new trial on board. This time, thanks to Professor Peter Schmidt´group and the Queen Mary University of London. BARBICAN is an international, randomised, open-label, Phase II study...
READ MORE...